Filing Details
- Accession Number:
- 0001209191-21-026666
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-14 16:43:36
- Reporting Period:
- 2021-04-12
- Accepted Time:
- 2021-04-14 16:43:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1664710 | Keros Therapeutics Inc. | KROS | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1808322 | Jennifer Lachey | C/O Keros Therapeutics, Inc. 99 Hayden Avenue, Suite 120, Building E Lexington MA 02421 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-04-12 | 5,300 | $0.30 | 76,487 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-04-12 | 998 | $59.10 | 75,489 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-12 | 3,473 | $59.99 | 72,016 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-12 | 729 | $61.08 | 71,287 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-12 | 100 | $61.72 | 71,187 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-04-12 | 5,300 | $0.00 | 5,300 | $0.30 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 135,005 | 2028-03-25 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $59.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.55 to $60.43 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.58 to $61.535 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.625 to $61.725 inclusive
- Immediately exercisable.
Billionaire Hedge Funds
